Biogen's secret campaign to bring its Alzheimer's drug back from the ashes

Biogen Inc's shock decision this week to bring its experimental Alzheimer's drug back from the scrap heap was born out of “top secret" meetings, non-disclosure agreements and six months of hashing over trial data with scientists, regulators and statisticians, researchers told Reuters.